Oxidative and antioxidative status after anthracycline-based chemotherapy in breast cancer patients

被引:1
|
作者
Alacacioglu, A. [1 ]
Kebapcilar, L. [2 ]
Pamuk, B. Onder [2 ]
Sop, G. [2 ]
Kucukiravul, C. [2 ]
Bozkaya, G. [3 ]
Yuksel, A. [2 ]
Alacacioglu, I. [4 ]
Sari, I. [2 ]
机构
[1] Bozyaka Res & Training Hosp, Dept Med Oncol, TR-35360 Izmir, Turkey
[2] Bozyaka Res & Training Hosp, Dept Internal Med, TR-35360 Izmir, Turkey
[3] Bozyaka Res & Training Hosp, Dept Biochem, TR-35360 Izmir, Turkey
[4] Ataturk Training & Res Hosp, Dept Hematol, Izmir, Turkey
来源
JOURNAL OF BUON | 2013年 / 18卷 / 03期
关键词
anthracycline; breast cancer; SOD; TBARS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The present study was undertaken to evaluate the effects of adjuvant anthracycline-based chemotherapy on thiobarbituric acid reactive substances (TBARS) and superoxide dismutase (SOD) levels in patients with breast cancer who had undergone surgery. Methods: Body mass index (BMI), serum lipids (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides), serum TBARS and SOD values were assessed in 30 patients with stage III breast cancer receiving adjuvant anthracydine-based chemotherapy. Results: Anthracycline-based chemotherapy had no effect on BMI, blood pressure and lipid profile. A significant elevation was noted in TBARS (5.5 +/- 0.6 vs 5.9 +/- 0.9}anon; p=0.038) and a significant reduction to baseline values in SOD levels (226.5 +/- 61.0 vs 203.1 +/- 48.3 U/mL; p=0.037) in patients following 6 cycles of adjuvant chemotherapy. Conclusion: The TBARS levels increased, whereas the SOD levels descreased after anthracycline-based chemotherapy. We suggest that oxidative stress is not always detrimental, as it can be beneficial in cancer treatment.
引用
收藏
页码:614 / 618
页数:5
相关论文
共 50 条
  • [1] Predictive factors for anthracycline-based chemotherapy for human breast cancer
    Miyoshi, Yasuo
    Kurosumi, Masafumi
    Kurebayashi, Junichi
    Matsuura, Nariaki
    Takahashi, Masato
    Tokunaga, Eriko
    Egawa, Chiyomi
    Masuda, Norikazu
    Kono, Seishi
    Morimoto, Koji
    Kim, Seung Jin
    Okishiro, Masatsugu
    Yanagisawa, Tetsu
    Ueda, Satsuki
    Taguchi, Tetsuya
    Tamaki, Yasuhiro
    Noguchi, Shinzaburo
    BREAST CANCER, 2010, 17 (02) : 103 - 109
  • [2] Predictive factors for anthracycline-based chemotherapy for human breast cancer
    Yasuo Miyoshi
    Masafumi Kurosumi
    Junichi Kurebayashi
    Nariaki Matsuura
    Masato Takahashi
    Eriko Tokunaga
    Chiyomi Egawa
    Norikazu Masuda
    Seishi Kono
    Koji Morimoto
    Seung Jin Kim
    Masatsugu Okishiro
    Tetsu Yanagisawa
    Satsuki Ueda
    Tetsuya Taguchi
    Yasuhiro Tamaki
    Shinzaburo Noguchi
    Breast Cancer, 2010, 17 : 103 - 109
  • [3] Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients
    Wang, Zhan
    Chen, Juan
    Zhong, Mei-Zuo
    Huang, Juan
    Hu, Yuan-Ping
    Feng, De-Yun
    Zhou, Zhi-Jiao
    Luo, Xiao
    Liu, Zhao-Qian
    Jiang, Wu-Zhong
    Zhou, Wei-Bing
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 535 - 543
  • [4] Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients
    Mina, Alain
    Rafei, Hind
    Khalil, Maya
    Hassoun, Yasmine
    Nasser, Zeina
    Tfayli, Arafat
    BMC CANCER, 2015, 15
  • [5] Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients
    Zhan Wang
    Juan Chen
    Mei-Zuo Zhong
    Juan Huang
    Yuan-Ping Hu
    De-Yun Feng
    Zhi-Jiao Zhou
    Xiao Luo
    Zhao-Qian Liu
    Wu-Zhong Jiang
    Wei-Bing Zhou
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 535 - 543
  • [6] Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients
    Alain Mina
    Hind Rafei
    Maya Khalil
    Yasmine Hassoun
    Zeina Nasser
    Arafat Tfayli
    BMC Cancer, 15
  • [7] Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer
    Mills, Paul J.
    Ancoli-Israel, Sonia
    Parker, Barbara
    Natarajan, Loki
    Hong, Suzi
    Jain, Shamini
    Sadler, Georgia R.
    von Kaenel, Roland
    BRAIN BEHAVIOR AND IMMUNITY, 2008, 22 (01) : 98 - 104
  • [8] The Double-Edged Sword: Controversies in Anthracycline-Based Chemotherapy for Breast Cancer
    Kota K.J.
    Brufsky A.M.
    Current Breast Cancer Reports, 2017, 9 (4) : 210 - 216
  • [9] Neutrophil count is not associated with infection episodes in breast cancer patients treated with anthracycline-based chemotherapy
    Mendonca, M. A. O.
    Pereira, A. H. M.
    Silva, S. R.
    Mardegan, M. C.
    Murta, E. F. C.
    Tavares-Murta, B. M.
    EUROPEAN JOURNAL OF CANCER CARE, 2009, 18 (02) : 184 - 190
  • [10] HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
    Yao, L.
    Liu, Y.
    Li, Z.
    Ouyang, T.
    Li, J.
    Wang, T.
    Fan, Z.
    Fan, T.
    Lin, B.
    Xie, Y.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1326 - 1331